China innovators D3 Bio, Sanegene each draw $100M+ rounds: Venture Report

Two fast-moving companies with a presence in China raised nine-figure series B rounds this week, as each moves forward with multiple clinical programs.

D3 Bio Inc. and Sanegene Bio Inc., both founded in 2020, have reached human testing for their lead programs quickly, and intend to bring programs into late-stage development with their latest rounds...